Legislators Introduce Follow-On Biologics Bill

Law360, New York (March 14, 2008, 12:00 AM EDT) -- A bill proposed by two members of the U.S. House of Representatives to create a pathway for generic or follow-on biologic drugs similar to the abbreviated new drug application for conventional generic drugs has, unsurprisingly, divided the pharmaceutical industry.

Reps. Anna G. Eshoo (D-Calif.) and Joe Barton (R-Texas) introduced the Pathway for Biosimilars Act, (H.R. 5629) on Thursday. The bill would create a regulatory pathway for U.S. Food and Drug Administration approval of follow-on biologics.

Eschoo said the bill would allow the FDA to decide whether...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.